{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T06:06:43Z","timestamp":1790921203692,"version":"4.1.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2007,10,1]],"date-time":"2007-10-01T00:00:00Z","timestamp":1191196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Opinion in Microbiology"],"published-print":{"date-parts":[[2007,10]]},"DOI":"10.1016\/j.mib.2007.08.007","type":"journal-article","created":{"date-parts":[[2007,10,24]],"date-time":"2007-10-24T07:17:25Z","timestamp":1193210245000},"page":"441-446","source":"Crossref","is-referenced-by-count":71,"title":["Late stage antibacterial drugs in the clinical pipeline"],"prefix":"10.1016","volume":"10","author":[{"given":"Steven J","family":"Projan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia A","family":"Bradford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.mib.2007.08.007_bib1","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.amjmed.2007.04.001","article-title":"Antimicrobial resistance prevention initiative\u2014an update: proceedings of an expert panel on resistance","volume":"120","author":"Moellering","year":"2007","journal-title":"Am J Med"},{"key":"10.1016\/j.mib.2007.08.007_bib2","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1086\/502231","article-title":"Community-acquired methicillin-resistant Staphylococcus aureus: an emerging pathogen","volume":"24","author":"Said-Salim","year":"2003","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.mib.2007.08.007_bib3","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1056\/NEJMoa042859","article-title":"A clone of methicillin-resistant Staphylococcus aureus among professional football players","volume":"352","author":"Kazakova","year":"2005","journal-title":"N Engl J Med"},{"issue":"Suppl 4","key":"10.1016\/j.mib.2007.08.007_bib4","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/j.1465-0691.2004.1006.x","article-title":"Antibacterial drug discovery: is it all downhill from here?","volume":"10","author":"Projan","year":"2004","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.mib.2007.08.007_bib5","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1086\/420937","article-title":"Trends in antimicrobial drug development: implications for the future","volume":"38","author":"Spellberg","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.mib.2007.08.007_bib6","series-title":"Bad Bugs, No Drugs; As Antibiotic Discovery Stagnates \u2026 A Public Health Crisis Brews","author":"IDSA","year":"2004"},{"key":"10.1016\/j.mib.2007.08.007_bib7","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.coph.2003.05.001","article-title":"Do we really need new anti-infective drugs?","volume":"3","author":"Rice","year":"2003","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.mib.2007.08.007_bib8","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1086\/499819","article-title":"Bad bugs need drugs: an update on the development pipeline from antimicrobial availability task force of the Infectious Diseases Society of America","volume":"42","author":"Talbot","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.mib.2007.08.007_bib9","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1128\/CMR.14.4.933-951.2001","article-title":"Extended-spectrum \u03b2-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat","volume":"14","author":"Bradford","year":"2001","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.mib.2007.08.007_bib10","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1128\/AAC.01370-06","article-title":"(Genome) size matters","volume":"51","author":"Projan","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mib.2007.08.007_bib11","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1093\/clinids\/23.1.118","article-title":"Ceftazidime-resistant Klebsiella pneumoniae isolates recovered at the Cleveland Department of Veterans Affairs Medical Center","volume":"23","author":"Rice","year":"1996","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.mib.2007.08.007_bib12","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1089\/109629600321326","article-title":"Decreased antimicrobial resistance following changes in antibiotic use","volume":"1","author":"Smith","year":"2000","journal-title":"Surg Infect"},{"key":"10.1016\/j.mib.2007.08.007_bib13","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S1471-4892(02)00197-2","article-title":"New (and not so new) antibacterial targets\u2014from where and when will the novel drugs come?","volume":"2","author":"Projan","year":"2002","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.mib.2007.08.007_bib14","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/nrd2201","article-title":"Drugs for bad bugs: confronting the challenges of antibacterial discovery","volume":"6","author":"Payne","year":"2007","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.mib.2007.08.007_bib15","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1586\/14787210.4.5.743","article-title":"Telavancin: a new lipoglycopeptide with multiple mechanisms of action","volume":"4","author":"Kanafani","year":"2006","journal-title":"Expert Rev Antiinfective Ther"},{"key":"10.1016\/j.mib.2007.08.007_bib16","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1517\/13543784.16.5.717","article-title":"Review of dalbavancin, a novel semisynthetic lipoglycopeptide","volume":"16","author":"Kim","year":"2007","journal-title":"Expert Opin Invest Drugs"},{"key":"10.1016\/j.mib.2007.08.007_bib17","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1586\/14787210.3.3.325","article-title":"Oritavancin: a new avenue for resistant Gram-positive bacteria","volume":"3","author":"Mercier","year":"2005","journal-title":"Expert Rev Antiinfective Ther"},{"key":"10.1016\/j.mib.2007.08.007_bib18","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1517\/13543784.16.4.419","article-title":"Anti-MRSA beta-lactams in development, with a focus on ceftobiprole: the first anti-MRSA beta-lactam to demonstrate clinical efficacy","volume":"16","author":"Bush","year":"2007","journal-title":"Expert Opin Invest Drugs"},{"key":"10.1016\/j.mib.2007.08.007_bib19","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1586\/14787210.5.2.185","article-title":"Faropenem: review of a new oral penem","volume":"5","author":"Schurek","year":"2007","journal-title":"Expert Rev Antiinfective Ther"},{"key":"10.1016\/j.mib.2007.08.007_bib20","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.diagmicrobio.2007.01.020","article-title":"Activity of garenoxacin, an investigational des-F(6)-quinolone, tested against pathogens from community-acquired respiratory tract infections, including those with elevated or resistant-level fluoroquinolone MIC values","volume":"58","author":"Jones","year":"2007","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.mib.2007.08.007_bib21","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.bcp.2005.10.052","article-title":"Dihydrofolate reductase inhibitors as antibacterial agents","volume":"71","author":"Hawser","year":"2006","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.mib.2007.08.007_bib22","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1586\/14787210.4.6.939","article-title":"Ramoplanin: a topical lipoglycodepsipeptide antibacterial agent","volume":"4","author":"Fulco","year":"2006","journal-title":"Expert Rev Antiinfective Ther"},{"key":"10.1016\/j.mib.2007.08.007_bib23","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1128\/AAC.00920-05","article-title":"Efficacy of cethromycin, a new ketolide, against Streptococcus pneumoniae susceptible or resistant to erythromycin in a murine pneumonia model","volume":"50","author":"Azoulay-Dupuis","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mib.2007.08.007_bib24","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.2165\/00003495-200767070-00006","article-title":"Comparative review of the carbapenems","volume":"67","author":"Zhanel","year":"2007","journal-title":"Drugs"},{"key":"10.1016\/j.mib.2007.08.007_bib25","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1128\/AAC.49.3.903-907.2005","article-title":"Emergence of resistance to rifampin and rifalazil in Chlamydophila pneumoniae and Chlamydia trachomatis","volume":"49","author":"Kutlin","year":"2005","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Current Opinion in Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1369527407001221?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1369527407001221?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,3]],"date-time":"2019-01-03T06:29:31Z","timestamp":1546496971000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1369527407001221"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,10]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2007,10]]}},"alternative-id":["S1369527407001221"],"URL":"https:\/\/doi.org\/10.1016\/j.mib.2007.08.007","relation":{},"ISSN":["1369-5274"],"issn-type":[{"value":"1369-5274","type":"print"}],"subject":[],"published":{"date-parts":[[2007,10]]}}}